Results: AVO

Search articles by EPIC code
EPIC AVO
views

Advanced Oncotherapy – Has Odey Doubled Down In Face Of Embarrassment Of Insolvency?

AIM-listed Advanced Oncotherapy (AVO) has announced that Odey Asset Management is coughing up another £4.5 million as part of a £6 million fundraise to add to its investment in March of £2 million, again at 25p a pop – the par price. So is this an act of faith by Odey, or a case of if you owe the bank a million quid then it is the bank which has a problem?

EPIC AVO
views

Advanced Oncotherapy – Yet Another Placing To Kick The Fat Lady Down The Road By Only A Few Inches

AIM-listed Advanced Oncotherapy (AVO) is certainly keeping its Brokers – SI Capital and Allenby – busy. Only in April the company raised £1.7 million, although the funds weren’t in the bank when the announcement went out. In March the company rattled the tin for £2 million – plus an additional loan of another £1.5 million. Now it has rattled the tin once again – to raise just £800,000 (before expenses) as the company strains to keep its head above water.

EPIC AVO
views

Advanced Oncotherapy – Flip-flop Delay To Fundraise!

On 12th April 2022 AIM-listed Advanced Oncotherapy (AVO) announced an equity fundraise of £1.735 million at 25p a pop – a premium to market, but only at par price. We were told that the fundraise has been conducted through a direct subscription with the Company (the "Subscription") for a total of 6,940,000 new ordinary shares. So the money was in the bank, right? Wrong….

EPIC AVO
views

Advanced Oncotherapy – When’s The Placing As Cash-Crisis Mounts Amid Shares Falling Below Par

I noted at the beginning of this month that AIM-listed Advanced Oncotherapy (AVO) needs to get a fundraise away pronto, but that its shares were threatening to drop below the nominal price of 25p, below which it cannot issue new shares by law. On Friday the shares closed at 24p (mid) and I would suggest that Advanced – or, rather, its shareholders – have a big problem.

EPIC AVO
views

Advanced Oncotherapy – Ignore Director Buying As Placing Approaches

AIM-listed and surely sort of cash Advanced Oncotherapy (AVO) announced yesterday morning that Prof Stephen Myers, executive director and the chairman of ADAM – Advanced’s development team in Geneva – had bought a total of 140,000 shares. At 27.64p (on average) that is £38,700 worth of stock. It sounds quite impressive, but this is certainly not a situation where it is advisable to follow director buying. In fact, I take the opposite view: the shares are a sell.

EPIC AVO
views

Advanced Oncotherapy – Good News Of Another Delay! Er.....?

AIM-listed Advanced Oncotherapy (AVO) has announced that its first proton beam therapy unit at Daresbury has once again been delayed. First it was due in 2021, then the end of 2021, then Q1 2022….now we are told more tests during Q2 and then finalisation of the integration of the remaining high energy accelerating modules and reaching the 230MeV target over the summer. That sounds like Q3 for Mr Godot to finally make an appearance. Or not.

Page 1 of 25 (248 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|